Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

p-Tyr Inhibitors

p-Tyr Inhibitors, also known as phospho-Tyrosine inhibitors, comprise a significant chemical class characterized by their ability to interact with and modulate proteins containing phosphorylated tyrosine residues. Phospho-tyrosine, a post-translational modification of the amino acid tyrosine, serves as a pivotal molecular switch in a wide range of cellular processes. These inhibitors play a crucial role in unraveling the intricate signaling networks that govern cell behavior by specifically binding to and interfering with phospho-tyrosine-mediated interactions.

Structurally, p-Tyr inhibitors exhibit distinct features that facilitate their engagement with phospho-tyrosine sites within target proteins. Often possessing well-defined three-dimensional architectures, these inhibitors are designed to complement the spatial arrangement of phospho-tyrosine-containing binding pockets. This allows for precise and effective interaction, disrupting the phospho-tyrosine-mediated functions of the protein. Additionally, p-Tyr inhibitors typically incorporate functional groups that form critical non-covalent interactions, such as hydrogen bonding and van der Waals forces, with the phospho-tyrosine residues. These interactions contribute to the high specificity and affinity of the inhibitors for their target sites. Research in the realm of p-Tyr inhibitors is a dynamic field that seeks to uncover the fundamental molecular mechanisms underpinning diverse cellular phenomena. By elucidating the interactions between these inhibitors and phospho-tyrosine-containing proteins, scientists gain insights into the intricate regulatory processes that dictate cellular responses.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib is an inhibitor of multiple tyrosine kinases

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Targets multiple tyrosine kinases, approved for CML and ALL.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Blocks EGFR tyrosine kinase, used in non-small cell lung cancer.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual HER2 and EGFR inhibitor, used for HER2+ breast cancer in research studies.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$184.00
$321.00
2
(0)

Targets multiple tyrosine kinases, used in idiopathic pulmonary fibrosis.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Inhibits multiple receptor tyrosine kinases, used in renal cell carcinoma.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$175.00
$983.00
2
(1)

Potent Bcr-Abl inhibitor, indicated for resistant CML and ALL.

5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine

1032900-25-6sc-505041
1 mg
$230.00
(0)

ALK and ROS1 inhibitor, used in ALK-positive NSCLC.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

Irreversible ErbB family blocker, used in NSCLC with EGFR mutations.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Targets multiple receptor kinases, used in renal cell carcinoma.